Relapsing Multiple Sclerosis (RMS) - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 53 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Relapsing Multiple Sclerosis (RMS) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Relapsing Multiple Sclerosis (RMS) - Pipeline Review, H2 2014', provides an overview of the Relapsing Multiple Sclerosis (RMS)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Relapsing Multiple Sclerosis (RMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Multiple Sclerosis (RMS) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Relapsing Multiple Sclerosis (RMS)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Relapsing Multiple Sclerosis (RMS) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Relapsing Multiple Sclerosis (RMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Relapsing Multiple Sclerosis (RMS) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Relapsing Multiple Sclerosis (RMS)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Relapsing Multiple Sclerosis (RMS) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Relapsing Multiple Sclerosis (RMS) Overview 6
Therapeutics Development 7
Pipeline Products for Relapsing Multiple Sclerosis (RMS) - Overview 7
Pipeline Products for Relapsing Multiple Sclerosis (RMS) - Comparative Analysis 8
Relapsing Multiple Sclerosis (RMS) - Therapeutics under Development by Companies 9
Relapsing Multiple Sclerosis (RMS) - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Relapsing Multiple Sclerosis (RMS) - Products under Development by Companies 12
Relapsing Multiple Sclerosis (RMS) - Companies Involved in Therapeutics Development 13
F. Hoffmann-La Roche Ltd. 13
Biogen Idec Inc. 14
Apitope International NV 15
Receptos, Inc. 16
Relapsing Multiple Sclerosis (RMS) - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
ocrelizumab - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
RPC-1063 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
BIIB-033 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
natalizumab - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ATXMS-1467 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Relapsing Multiple Sclerosis (RMS) - Recent Pipeline Updates 36
Relapsing Multiple Sclerosis (RMS) - Discontinued Products 43
Relapsing Multiple Sclerosis (RMS) - Product Development Milestones 44
Featured News & Press Releases 44
Jun 09, 2014: Receptos Reports Positive Phase 2 Results for RPC1063 in Relapsing Multiple Sclerosis 44
May 30, 2014: Genzyme's Lemtrada Resubmission Accepted for Review by FDA 44
Apr 07, 2014: Genzyme to Resubmit Lemtrada Application for FDA Review 45
Jan 06, 2014: Receptos Begins Enrollment of Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis 45
Dec 30, 2013: Genzyme Receives Complete Response Letter from FDA on Lemtrada (alemtuzumab) Application 46
Oct 03, 2013: Real-world evidence showed superiority of Novartis' Gilenya to reduce MS relapse rates compared to interferons or glatiramer acetate 46
Oct 03, 2013: Teva to Present Further Results of Twenty-Year Open-Label Extension Study of Glatiramer Acetate 20 mg Daily for Relapsing-Remitting Multiple Sclerosis 47
Sep 03, 2013: Apitope Announces Positive Results from Clinical Trial of ATX-MS-1467 in Relapsing Multiple Sclerosis 48
Jun 05, 2013: RedHill Biopharma Commences Patient Screening In Phase IIa Clinical Trial With RHB-104 For Multiple Sclerosis 49
Jun 05, 2013: Receptos Provides Update On Progress Of Lead Product Candidate RPC1063 50
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 53
Disclaimer 53

List of Tables
Number of Products under Development for Relapsing Multiple Sclerosis (RMS), H2 2014 7
Number of Products under Development for Relapsing Multiple Sclerosis (RMS) - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Relapsing Multiple Sclerosis (RMS) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 13
Relapsing Multiple Sclerosis (RMS) - Pipeline by Biogen Idec Inc., H2 2014 14
Relapsing Multiple Sclerosis (RMS) - Pipeline by Apitope International NV, H2 2014 15
Relapsing Multiple Sclerosis (RMS) - Pipeline by Receptos, Inc., H2 2014 16
Assessment by Monotherapy Products, H2 2014 17
Number of Products by Stage and Target, H2 2014 19
Number of Products by Stage and Mechanism of Action, H2 2014 21
Number of Products by Stage and Route of Administration, H2 2014 23
Number of Products by Stage and Molecule Type, H2 2014 25
Relapsing Multiple Sclerosis (RMS) Therapeutics - Recent Pipeline Updates, H2 2014 36
Relapsing Multiple Sclerosis (RMS) - Discontinued Products, H2 2014 43